Смертельно опасные лекарства и организованная преступность

15. Heres S., Davis J., Maino K., et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006; 163: 185–94.

16. Moffatt B., Elliott C. Ghost marketing. Perspect Biol Med. 2007; 50: 18–31.

17. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.

18. Healy D., Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003; 183: 22–7.

19. Sismondo S., Nicholson S. H. Publication planning 101: a report. J Pharm Pharmaceut Sci. 2009; 12: 273–9.

20. Gøtzsche P. C., Hrybjartsson A., Johansen H. K., et al. Ghost authorship in industry-initiated randomized trials. PLoS Med. 2007; 4: e19.

21. Yank V., Rennie D. Disclosure of researcher contributions: a study of original research articles in The Lancet. Ann Intern Med. 1999; 130: 661–70.

22. Flanagin A., Carey L. A., Fontanarosa P. B., et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. 1998; 280: 222–4.

23. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004; 34: 219–45.

24. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

25. Zuger A. How tightly do ties between doctor and drug company bind? New York Times. 2004 June 27.

26. Avorn J., Chen M., Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73: 4–8.

27. Prosser H., Almond S., Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam Pract. 2003; 20: 61–8.

28. Henry D., Doran E., Kerridge I., et al. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. Arch Intern Med. 2005; 165: 2493–6.

29. Campbell E. G., Gruen R. L., Mountford J., et al. A national survey of physician-industry relationships.N Engl J Med. 2007; 356: 1742–50.

30. Gagnon M.-A., Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5: e1.

31. Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.

32. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.

33. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.

34. Ziegler M. G., Lew P., Singer B. C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.

35. Steinman M. A., Harper G. M., Chren M. M., et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.

36. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885–90.

37. Chren M. M., Landefeld C. S. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.

38. Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992; 102: 270–3.

39. Morgan S. G., Bassett K. L., Wright J. M., et al. ‘Breakthrough’ drugs and growth in expenditure on prescription drugs in Canada. BMJ. 2005; 331: 815–6.

40. Johansen H. K., Gøtzsche P. C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.

41. Jørgensen K. J., Johansen H. K., Gøtzsche P. C. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006; 7: 3.

42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97.